About the Program

For more than three decades, the pharmacogenomics program has been a flagship pillar of the Department of Pharmacy and Pharmaceutical Sciences at St. Jude. Scientists and clinicians within this program have pioneered pharmacogenomics discovery research and clinical implementation on a global scale. Our work focuses on elucidating the genetic basis of inter-patient variation in drug effects and then using this information to individualize pharmacotherapy therby ensuring maximal efficacy and minimal toxicity. Our discovery research uncovered a plethora of pharmacogenetic variants influencing common anti-cancer drugs, as described in our high-impact publications (NEJM, JAMA, Nature Medicine, Nature Genetics), and our implementation efforts have served as a model for others including housing the Clinical Pharmacogenetic Implementation Consortium (CPIC) and our work in this space serves as a model for others across the world. These efforts have enabled the clinical implementation of pharmacogenomics, shifting the paradigm of precision medicine in pediatric oncology and beyond.   

Program Priorities


Jun J. Yang, PhD
Director, Pharmacogenomics Program
Vice Chair, Dept of Pharmacy and Pharmaceutical Sciences

Cyrine Haidar, PharmD, BCPS, BCOP
Associate Member, St. Jude Faculty
Clinical Pharmacogenomics Coordinator

Kristine Crews, PharmD, BCPS
Clinical Pharmacogenomics Residency Director
Co-Director, Pharmacokinetics Shared Resource
Translational Research Lab Director

Kelly Caudle, PharmD, PhD
Associate Member, St. Jude Faculty
Director, CPIC

James Hoffman, PharmD
Member, St. Jude Faculty
Senior Vice President, Quality and Safety
Chief Patient Safety Officer